3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Multiple Myeloma
1
Interventions
Cisplatin
1041
Cyclophosphamide
973
Carboplatin
954
Radiotherapy
893
Bevacizumab
847
Gemcitabine
817
pembrolizumab
759
Paclitaxel
738
Docetaxel
734
Oxaliplatin
706
Capecitabine
649
Fluorouracil
564
Rituximab
559
Nivolumab
506
Dexamethasone
487
Etoposide
468
Doxorubicin
458
Irinotecan
442
Drug Therapy
402
Leucovorin
377
Cytarabine
342
Cetuximab
340
Lenalidomide
326
Trastuzumab
323
Pemetrexed
315
durvalumab
295
Filgrastim
287
Magnetic Resonance Spectroscopy
278
Temozolomide
275
Prednisone
274
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
darlin protein, Dictyostelium
×
Clear all
NCT03450057
2024-03-29
DARE
Hellenic Society of Hematology
Phase 2
Completed
38 enrolled
16 charts